论文部分内容阅读
目的观察氧驱动雾化吸入普米克令舒联合博利康尼、沐舒坦治疗中、重度哮喘急性发作的临床疗效。方法选择64例中、重度支气管哮喘急性发作的患者,随机分为基线资料匹配的治疗组和对照组。对照组32例,采用常规综合疗法;治疗组32例,在常规治疗基础上给予氧驱动雾化吸入普米克令舒联合博利康尼、沐舒坦;观察2组症状、体征消失天数、肺功能改善情况及临床疗效。结果治疗5d后评价,2组治疗后肺功能指标[FEV1、FEV1/FVC(%)、FEV1/预计(%)]均上升(P均<0.05),且治疗组治疗后各项指标均高于对照组(P均<0.05);治疗组症状、体征消失天数少于对照组(P均<0.05)。治疗组总有效率96.9%,稍高于对照组的87.5%,但差异无统计学意义(P>0.05)。结论常规综合治疗基础上氧驱动雾化吸入普米克令舒联合博利康尼、沐舒坦能迅速缓解中、重度哮喘的急性发作,疗效优于常规综合治疗。
Objective To observe the clinical efficacy of aerosol-driven inhalation of pulmicort and combiblipanib and mucosolvan in the treatment of acute exacerbation of moderate and severe asthma. Methods Sixty-four patients with acute exacerbation of moderate and severe bronchial asthma were randomly divided into treatment group and control group matched with baseline data. Control group of 32 cases, the use of conventional combination therapy; treatment group of 32 patients on the basis of conventional therapy with oxygen inhalation Pulmicort respules combined with berlitconazole, ambroxol; observed two groups of symptoms, signs disappear days, lung function improvement Situation and clinical efficacy. Results After 5 days of treatment, the indexes of pulmonary function [FEV1, FEV1 / FVC (%), FEV1 / predicted] increased after treatment in both groups (all P <0.05) (P <0.05). The number of symptoms and signs disappeared in the treatment group was shorter than that in the control group (all P <0.05). The total effective rate was 96.9% in the treatment group, slightly higher than 87.5% in the control group, but the difference was not statistically significant (P> 0.05). Conclusion Conventional comprehensive treatment based on oxygen-driven inhalation of pulmicort respules combined with Boli Kang Ni, Mucosolvan can quickly alleviate the acute attack of moderate and severe asthma, the effect is superior to the conventional comprehensive treatment.